Ervogastat Alone and Combined with Clesacostat for Metabolic Dysfunction-Associated Steatohepatitis with Advanced Fibrosis: Insights from the MIRNA Phase 2 Trial
Posted inClinical Updates Wellness & Lifestyle

Ervogastat Alone and Combined with Clesacostat for Metabolic Dysfunction-Associated Steatohepatitis with Advanced Fibrosis: Insights from the MIRNA Phase 2 Trial

The MIRNA study evaluated ervogastat, alone and with clesacostat, in patients with biopsy-confirmed MASH and F2-F3 fibrosis, showing combination therapy achieved significant efficacy in resolving MASH without fibrosis worsening and a manageable safety profile.